Beroni Group Limited


Beroni GroupBeroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit



Beroni Group Limited (NSX:BTG) Dr Richard Buchta Appointed as Director

🕔6/30/2020 11:37:00 AM 615

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has appointed Dr. Richard Buchta as an independent non-executive director of the Company

Read Full Article

Beroni Group Limited (NSX:BTG) Issue of shares

🕔6/23/2020 7:14:00 AM 986

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that, the Company has completed the issue of 2,390,000 fully paid ordinary shares to the Directors, employees and scientists.

Read Full Article

Beroni Group Limited (NSX:BTG) Issue of US$2.97m Convertible Notes to Fund Growth

🕔6/9/2020 1:07:00 PM 925

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has raised US$2.97 million via the issue of convertible notes to professional and sophisticated investors in Japan.

Read Full Article


  • This Page Viewed: (Last 7 Days: 65) (Last 30 Days: 840) (Since Published: 841) 

Company Data

  • Suite 401, 447 Kent Street
    Sydney, NSW 2000
  • Telephone
  • +61 2 8051 3055 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Pharmaceutical 
  • Homepage

Social Media